<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02132689</url>
  </required_header>
  <id_info>
    <org_study_id>FNO-KVO-3</org_study_id>
    <nct_id>NCT02132689</nct_id>
  </id_info>
  <brief_title>Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism</brief_title>
  <acronym>CONTACT-SPE</acronym>
  <official_title>Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism in Context of Pulmonary Hypertension, Right Heart Failure and Patient Functional Ability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Municipal Hospital Ostrava Fifejdy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Silesian Hospital Opava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently there is no clear guidance for the treatment of moderate risk of pulmonary
      embolism. The aim of the study is to compare two different therapeutic modalities - standard
      anticoagulation versus thrombolytic treatment followed by anticoagulation in standard regimen
      as stated in the pulmonary embolism guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard treatment of moderate risk pulmonary embolism constitutes of sole anticoagulation
      therapy. In case of troponin positivity and/or echocardiographic findings as i.e. thrombi in
      RV thrombolytic therapy should be considered. The aim of this trial is to compare the two
      treatment modalities in their ability to reduce/predict 12 month end-point: pulmonary
      hypertension, right ventricular failure, exercise capacity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical manifestations of right ventricular failure and pulmonary hypertension and cardiovascular-related death</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome of the study is to follow clinical manifestations of right ventricular failure (assessed according to the New York Heart Association /NYHA/ classification).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary hypertension</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome of the study is to follow pulmonary hypertension (measured in mmHg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular-related deaths</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome of the study is to follow the number of cardiovascular-related deaths within the time frame of 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic manifestations of right ventricular failure and pulmonary hypertension.</measure>
    <time_frame>12 months</time_frame>
    <description>The secondary outcome measure of the study is to follow echocardiographic manifestations of right ventricular failure (TdiSm).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Actilyse</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thrombolytic therapy: Patients treated with initial thrombolytic therapy (Actilyse) followed with anticoagulant therapy (unfractionated/low-molecular weight heparin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UHF/LMWH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anticoagulation therapy: Patients treated with anticoagulation therapy only (unfractionated/low-molecular weight heparin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actilyse (Thrombolytic therapy)</intervention_name>
    <arm_group_label>Actilyse</arm_group_label>
    <other_name>Actilyse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparine (Standard anticoagulation therapy)</intervention_name>
    <arm_group_label>Actilyse</arm_group_label>
    <arm_group_label>UHF/LMWH</arm_group_label>
    <other_name>unfractionated/low-molecular weight heparine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate risk pulmonary embolism as defined by the European Society of Cardiology
             /ESC/ guidelines

          -  signed informed consent

        Exclusion Criteria:

          -  patient not willing to sigh informed consent

          -  absolute contraindication of thrombolysis

          -  inability to obtain meaningfull echocardiographic imagesÂ¨

          -  pulmonary arterial hypertension

          -  known right ventricular failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Radovan Stancik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, University Hospital Ostrava</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Silesian Hospital Opava</name>
      <address>
        <city>Opava</city>
        <zip>746 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2014</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate Risk Acute Pulmonary Embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Fibrinolytic Agents</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

